News

Xarelto is dangerous, New York Times found evidence against Pharmaceutical.

new-york-times-hed-2013
Written by admin

As per New York Times journalist the manufacturers of Xarelto (rivaroxaban), Bayer and Johnson and Johnson (J&J hiding some useful information about the serious dangers associated with the medication. According to the magazine reporter they have found evidence against the pharmaceutical companies that they already knew the side effects and dangers of Xarelto. More than 5,000 cases have been filed in the court and out of which at least 500 of them alleging patients’ deaths. The antidote for Xarelto is not available. So, many patients taking this medication suffered permanent injuries and in rare cases death.

An another incident took place in Texas where a lady was prescribed Xarelto by her doctor as a method of treatment for her atrial fibrillation condition, which can put sufferers at an increased risk for the occurrence of strokes. It is common for blood thinning drugs to be prescribed preventatively in these circumstances. In this case lady took Xarelto for only 5 month’s time before suddenly suffering from a life-threatening internal bleeding episode. Her complaint states that this dangerous and substantial bleed left her with long-term health problems requiring lengthy and costly specialized care. She filed a lawsuit against AG and Johnson & Johnson subsidiary Pharmaceuticals in the Eastern District of New York. The lady claims that new-generation, blood-thinning drug Xarelto caused her to suffer from dangerous health complications and the manufacturers failed to appropriately warn patients about the consequential risks linked with their anticoagulant.

A famous clinical trial, the ROCKET-AF trial was made to test the safety and effectiveness of the drugs. Findings from this trial provided sufficient evidence to demonstrate that Bayer’s blood thinner was the better choice to prevent strokes and blood clots formation in patients with Atrial Fibrillation. As the result was in the favor of Bayer’s FDA granted approval to the drug on July 2011. Earlier this year, in February 2016, researchers from the Duke Institute that performed the ROCKET-AF trial, provided a new in-depth analysis of the new blood thinner’s efficacy and safety outcomes after five years of use. The test results reveal that the previous findings of rivaroxaban’s superiority over Warfarin were false. The Duke researchers were hiding precious information as they were conspirator with Bayer and J&J.

More than 3,000 lawsuits filed from across the nation against Xarelto. In 2011, Xarelto was approved by the U.S. Food and Drug Administration, As the drug is surrounded  by more than 3,000 lawsuits this approval has now become a topic of increasing controversy. Xarelto received two ‘black box’ warnings from the FDA. These warnings are the strictest warning a product can receive before being pulled completely from the market.

About the author

admin

Leave a Comment